PRIMARY STUDY
Non-psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors-, endocannabinoids-, and NF-κB-mediated signaling
Key Findings: The phytocomplex of Cannabis Sativa extract showed significantly more anti-inflammatory activity in activated microglial cells than isolated cannabidiol (CBD) and β-caryophyllene (CAR) at the same concentration. This study could lead to promising therapeutics in reducing neuroinflammatory and related diseases.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): Italy
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Cannabinoid (unspecified), Endocannabinoid (unspecified), Other Related Compounds
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype III
Terpenes Studied: ß-Caryophyllene, Humulene
Receptors Studied: CB2, PPAR - Gamma
Ligands Studied: Pro-inflammatory cytokines
Route of Administration: In vitro
Citation: Borgonetti V, et al. Non-psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors-, endocannabinoids-, and NF-κB-mediated signaling. Phytother Res. 2022; 36:2246-2263. doi: 10.1002/ptr.7458
Authors: Borgonetti V, Benatti C, Governa P, Isoldi G, Pellati F, Alboni S, Tascedda F, Montopoli M, Galeotti N, Manetti F, Miraldi E, Biagi M, Rigillo G
